Affinage

KDM3A

Lysine-specific demethylase 3A · UniProt Q9Y4C1

Length
1321 aa
Mass
147.3 kDa
Annotated
2026-06-10
100 papers in source corpus 51 papers cited in narrative 49 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

KDM3A (JMJD1A/JHDM2A) is an iron(II)/2-oxoglutarate-dependent JmjC dioxygenase that removes mono- and di-methyl marks from histone H3K9, acting as a transcriptional coactivator that converts repressive H3K9me1/me2 into permissive chromatin at the promoters and enhancers of developmental, metabolic, and oncogenic gene programs (PMID:17938240, PMID:29526734). Its catalytic mechanism depends on a metal center: nickel ions inhibit activity by displacing the active-site iron (PMID:20042601), and iron availability supplied by lysosomal ferritinophagy limits its demethylase output during adipogenesis (PMID:37158274). Catalysis is rendered efficient by homodimerization, which juxtaposes two active sites to channel the monomethyl intermediate to the fully demethylated product (PMID:24214985). KDM3A operates in dynamic opposition to the GLP/G9a H3K9 methyltransferase, and this methylation–demethylation balance governs euchromatic H3K9 hypomethylation, pluripotency gene expression, and a developmental switch exemplified by Sry-dependent male sex determination, where loss of KDM3A causes male-to-female sex reversal in mice (PMID:29526734, PMID:28949961, PMID:24009392). Beyond chromatin, KDM3A demethylates non-histone substrates: it removes monomethylation from p53-K372 to suppress apoptosis (PMID:27270439) and from PGC-1α-K224, an oxygen-sensitive reaction whose loss under hypoxia restrains mitochondrial biogenesis (PMID:31629659). KDM3A is a hub for signal-responsive transcription, being transcriptionally induced by HIF-1α under hypoxia to drive glycolytic genes (PMID:18984585, PMID:18538129, PMID:22645302, PMID:28263974), and post-translationally tuned by phosphorylation — PKA at S265 downstream of β-adrenergic signaling enables a demethylase-independent scaffold function that recruits SWI/SNF and PPARγ to drive chromatin looping in adipocyte thermogenesis (PMID:25948511, PMID:29674659), while ACK1 (Y1114) and JAK2 tyrosine phosphorylation enhance its coactivator output (PMID:25148682, PMID:30377265). Protein abundance is set by STUB1-mediated degradation, antagonized by p300-dependent K421 acetylation that recruits BRD4, and by HUWE1-mediated noncanonical K918 ubiquitination (PMID:32522824, PMID:32238799). KDM3A also acts through demethylase-independent routes, scaffolding splicing factors HNRNPF and SRSF3 (via ARID1A/SWI/SNF) to control alternative splicing (PMID:29712835, PMID:34321328) and coordinating actin dynamics with intraflagellar transport to maintain cilia stability (PMID:28246120). Across many cancers KDM3A behaves as a pro-tumorigenic coactivator for receptor- and oncogene-driven programs including ER, AR, c-Myc, Wnt/β-catenin, and Hippo/YAP-TEAD (PMID:25488809, PMID:26279298, PMID:29802196, PMID:30649550).

Mechanistic history

Synthesis pass · year-by-year structured walk · 23 steps
  1. 2007 High

    Established KDM3A as an H3K9me2 demethylase that activates transcription, answering whether this JmjC protein had a defined chromatin-modifying function with biological consequence.

    Evidence RNAi knockdown and ChIP at pluripotency gene promoters in mouse ES cells with differentiation readout

    PMID:17938240

    Open questions at the time
    • Did not resolve substrate specificity between me1 and me2
    • No structural basis for catalysis
    • Genome-wide target scope unknown
  2. 2008 High

    Placed KDM3A downstream of hypoxia signaling by showing HIF-1α directly induces its expression, linking the demethylase to oxygen sensing.

    Evidence ChIP of HIF-1α at JMJD1A promoter HREs, HIF-1 siRNA epistasis, in vitro demethylase assay (replicated across two labs)

    PMID:18538129 PMID:18984585

    Open questions at the time
    • Did not define which target genes KDM3A regulates under hypoxia
    • Direct enzymatic role at hypoxic loci not yet shown
  3. 2009 High

    Defined the metal-dependent catalytic mechanism and a mode of inhibition by demonstrating nickel displaces active-site iron, explaining environmental modulation of activity.

    Evidence In vitro stoichiometric Ni/Fe demethylase assays, XAS structural validation, cell-based inhibition

    PMID:20042601

    Open questions at the time
    • Physiological relevance of nickel exposure unaddressed
    • Did not measure oxygen dependence of catalysis
  4. 2012 High

    Connected HIF-1α-induced KDM3A to glycolytic gene activation via direct demethylation and chromatin looping, establishing it as a functional hypoxia effector.

    Evidence ChIP-seq, 3C, and RNAi at the GLUT3 locus

    PMID:22645302

    Open questions at the time
    • Mechanism of recruitment to specific loci not defined
    • Whether looping requires demethylase activity unresolved
  5. 2013 High

    Demonstrated a developmental switch role by showing KDM3A controls Sry expression, with loss causing sex reversal — establishing a non-redundant in vivo function.

    Evidence Jmjd1a knockout mice with sex-reversal phenotype and ChIP at the Sry locus

    PMID:24009392

    Open questions at the time
    • Opposing methyltransferase not yet identified
    • Recruitment mechanism to Sry unknown
  6. 2013 High

    Revealed the catalytic basis for efficient me2-to-me0 conversion through homodimerization-driven substrate channeling.

    Evidence In vitro demethylation kinetics with size-exclusion, native gel, and WT/inactive heterodimer analysis

    PMID:24214985

    Open questions at the time
    • No crystal structure of the dimer
    • Whether dimerization is regulated in cells unknown
  7. 2013 High

    Extended KDM3A function to viral chromatin by showing it partners with KSHV LANA to keep viral promoters H3K9-hypomethylated, broadening its coactivator repertoire.

    Evidence Reciprocal Co-IP with purified proteins, ChIP-chip on KSHV episome, knockdown

    PMID:23576503

    Open questions at the time
    • Single-virus context
    • Generalizability to host loci not addressed here
  8. 2014 High

    Established KDM3A as a catalytically required coactivator of nuclear hormone receptor signaling (ER) and identified a tyrosine kinase (ACK1) input that boosts its activity, defining signal-to-chromatin coupling in cancer.

    Evidence ChIP, catalytic mutant rescue for ER target genes; in vitro ACK1 kinase assay mapping Y1114 with ChIP/inhibitor epistasis

    PMID:25148682 PMID:25488809

    Open questions at the time
    • How Y1114 phosphorylation enhances catalysis mechanistically unclear
    • Reciprocal regulation of ACK1 not addressed
  9. 2014 High

    Uncovered cytoplasmic and chaperone-dependent dimensions of KDM3A, showing Hsp90-client status and roles in spermatid cytoskeletal structures beyond chromatin.

    Evidence Two Kdm3a mouse models, EM, fractionation, Hsp90 inhibition, immunolocalization

    PMID:24554764

    Open questions at the time
    • Direct cytoskeletal binding partners not defined here
    • Separation of nuclear vs cytoplasmic contributions incomplete
  10. 2015 High

    Discovered the demethylase-independent scaffold function: PKA-driven S265 phosphorylation recruits SWI/SNF and PPARγ to enable rapid chromatin looping, dissociating scaffold from enzymatic roles.

    Evidence PKA phosphorylation assay, Co-IP, ChIP, 3C, S265A mutant rescue in brown adipocytes

    PMID:25948511

    Open questions at the time
    • Structural basis for phospho-dependent complex assembly unknown
    • Generality beyond adipocytes not yet tested
  11. 2015 High

    Showed KDM3A stabilizes c-Myc protein via a catalysis-independent interaction with HUWE1, in addition to activating c-Myc transcription, revealing dual oncogenic mechanisms.

    Evidence Co-IP, ubiquitination assay, ChIP, catalytic mutant analysis

    PMID:26279298

    Open questions at the time
    • How KDM3A blocks HUWE1 catalysis not defined
    • Whether this competes with HUWE1 acting on KDM3A itself unaddressed
  12. 2016 High

    Identified the first non-histone substrate, p53-K372me1, establishing KDM3A as a protein demethylase that suppresses apoptosis.

    Evidence In vitro demethylation of p53-K372me1 peptide, Co-IP, ChIP, RNAi

    PMID:27270439

    Open questions at the time
    • Specificity determinants for non-histone substrates unknown
    • Single lab
  13. 2016 High

    Expanded the oncogenic and mechanosensing repertoire, linking KDM3A levels and nuclear localization to ECM stiffness, anoikis (BNIP3/BNIP3L), and myeloma survival axes.

    Evidence Knockdown/localization on varying ECM, RNAi screen with ChIP at BNIP3/BNIP3L, HIF-1α→KDM3A→MALAT1 epistasis, KLF2/IRF4 ChIP and in vivo models

    PMID:26728187 PMID:27472901 PMID:27488962 PMID:29444873

    Open questions at the time
    • Mechanism coupling mechanosignaling to KDM3A abundance/localization unresolved
    • Context-dependence of pro- vs anti-survival roles not reconciled
  14. 2017 High

    Defined demethylase-independent splicing control through HNRNPF recruitment to AR pre-mRNA, broadening KDM3A function into RNA processing.

    Evidence Co-IP, RIP, minigene reporter, siRNA in prostate cancer cells

    PMID:29712835

    Open questions at the time
    • Whether chromatin recruitment couples to splicing not shown
    • Breadth of splicing targets undefined
  15. 2017 High

    Established the actin/cilia axis, showing KDM3A controls cilia stability through both actin gene transcription and direct cytoskeletal binding gating IFT entry.

    Evidence KDM3A knockout mouse with cilia phenotype, cytoskeleton binding, IFT imaging, ARP2/3 inhibitor and actin manipulation rescue

    PMID:28246120

    Open questions at the time
    • Molecular nature of the actin interaction undefined
    • Relationship to ciliopathy disease unconfirmed
  16. 2017 High

    Showed broad coactivator partnerships with transcription factors (c-Jun/AP-1 with Brg1, Snail, ETV1, ER71) driving tumor and vascular phenotypes, many requiring demethylase activity.

    Evidence ChIP at AP-1/Snail promoters, in vivo tumor and vascular injury models, catalytic mutant analyses

    PMID:16619273 PMID:28135625 PMID:28319067 PMID:28692045 PMID:32019811

    Open questions at the time
    • Determinants of which transcription factor KDM3A partners with in a given context unknown
    • Some early TF-interaction data assign a repressor role inconsistent with later coactivator findings
  17. 2018 High

    Resolved tissue-specific thermogenic logic, showing S265 phosphorylation drives demethylation-independent acute Ucp1 induction in BAT versus phosphorylation-plus-demethylation chronic induction in beige WAT via a PRDM16-PPARγ complex; also identified JAK2-STAT3 tyrosine-phospho coactivation.

    Evidence S265A and demethylase-mutant knock-in mice, Co-IP of PRDM16-PPARγ complex, 3C, ChIP; in vitro JAK2 kinase assay with Co-IP/ChIP

    PMID:29674659 PMID:30377265

    Open questions at the time
    • Site of JAK2 phosphorylation not mapped here
    • Integration of multiple kinase inputs on KDM3A not unified
  18. 2019 High

    Established KDM3A as an oxygen-sensitive non-histone demethylase of PGC-1α-K224, linking its high oxygen KM to hypoxic control of mitochondrial biogenesis.

    Evidence Co-IP, in vitro PGC-1α-K224me1 demethylation, oxygen-KM measurement, K224R mutant in cells and tumor xenografts

    PMID:31629659

    Open questions at the time
    • Whether other metabolic regulators are non-histone substrates unknown
    • In vivo oxygen-gradient relevance not directly measured
  19. 2019 High

    Mapped post-translational and post-transcriptional control of KDM3A abundance, identifying STUB1 degradation, p300-K421-acetylation/BRD4 stabilization, HUWE1-K918 ubiquitination, and PHF5A-driven splicing stabilization of KDM3A mRNA.

    Evidence Multiple Co-IPs, ubiquitination/acetylation site mapping, ChIP, clinical correlation; proteomics, splicing reporter, RNA-seq for PHF5A axis

    PMID:31054974 PMID:32238799 PMID:32522824

    Open questions at the time
    • Hierarchy/crosstalk among competing PTMs on KDM3A unresolved
    • Stimuli triggering each modification not fully defined
  20. 2019 High

    Broadened KDM3A's coactivator scope to Hippo/YAP-TEAD enhancers (p300 cooperation), condensin/heterochromatin during senescence, and pancreatic tumorigenesis via DCLK1.

    Evidence ChIP-seq with H3K9me2/H3K27ac, Co-IP with p300, Kdm3a KO mouse models, in vivo transformation/xenograft assays

    PMID:30649550 PMID:31442435 PMID:31704649

    Open questions at the time
    • Whether p300 cooperation is general across all KDM3A enhancers unknown
    • Direct vs indirect target distinction incomplete in several contexts
  21. 2021 High

    Defined the KDM3A/KDM3B paralog complex cooperating with OCT4/SOX2 and demethylase-independent splicing scaffolding with ARID1A/SRSF3, integrating enzymatic and non-enzymatic functions.

    Evidence IP-MS of KDM3A-KDM3B complex with ChIP-seq; Co-IP of KDM3A-ARID1A/SRSF3, RIP, S265 phosphorylation, catalytic mutant after DNA damage

    PMID:32457453 PMID:34042215 PMID:34321328

    Open questions at the time
    • Stoichiometry and architecture of the KDM3A/KDM3B complex undefined
    • How DNA damage signals to S265 phosphorylation unclear
  22. 2023 High

    Established iron supply via lysosomal ferritinophagy as a rate-limiting input to KDM3A demethylase activity during adipocyte differentiation, tying metabolic iron status to chromatin output.

    Evidence ChIP-seq, iron chelation/ferritinophagy inhibition, histone mass spectrometry, knockdown with differentiation readout

    PMID:37158274

    Open questions at the time
    • Generality of iron limitation to other cell types untested
    • Subcellular site of iron loading onto KDM3A unknown
  23. 2024 High

    Demonstrated demethylase-specific, tissue-selective metabolic functions in vivo: demethylase activity drives Pgc1a/b enhancer activation and beiging in scWAT but is dispensable for acute BAT thermogenesis, with loss causing obesity and insulin resistance.

    Evidence Demethylase-activity mutant knock-in mice, ChIP at Pgc1a/b enhancers, β-adrenergic stimulation, metabolic phenotyping

    PMID:38544573

    Open questions at the time
    • Molecular basis for tissue selectivity of demethylase requirement unresolved
    • Human metabolic relevance not directly tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the many regulatory inputs (kinase phosphorylations, competing ubiquitin/acetyl marks, dimerization, metal/oxygen status) are integrated to select between KDM3A's enzymatic and scaffold functions at a given locus remains unresolved, as does a high-resolution structural model of the full-length protein and its complexes.
  • No full-length structure or structural model of regulatory PTMs
  • Rules governing target-locus selection across contexts unknown
  • Quantitative crosstalk among competing PTMs not mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016491 oxidoreductase activity 5 GO:0140110 transcription regulator activity 5 GO:0060090 molecular adaptor activity 3 GO:0008092 cytoskeletal protein binding 2 GO:0042393 histone binding 2 GO:0140096 catalytic activity, acting on a protein 2
Localization
GO:0000228 nuclear chromosome 3 GO:0005634 nucleus 3 GO:0005829 cytosol 2 GO:0005856 cytoskeleton 2
Pathway
R-HSA-1266738 Developmental Biology 4 R-HSA-1643685 Disease 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-8953897 Cellular responses to stimuli 4 R-HSA-1430728 Metabolism 3 R-HSA-4839726 Chromatin organization 3 R-HSA-8953854 Metabolism of RNA 3 R-HSA-5357801 Programmed Cell Death 2
Partners
ARID1AEP300HNRNPFHUWE1KDM3BPPARGPRDM16STUB1
Complex memberships
KDM3A/KDM3B H3K9 demethylase complexPRDM16-PPARγ-JMJD1A complexSWI/SNF (with PPARγ) scaffold complex

Evidence

Reading pass · 49 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2007 Jmjd1a (KDM3A) demethylates H3K9me2 at the promoter regions of Tcl1, Tcfcp2l1, and Zfp57 in mouse embryonic stem cells, positively regulating the expression of these pluripotency-associated genes. Jmjd1a depletion leads to ES cell differentiation accompanied by reduction of ES cell-specific gene expression. RNAi knockdown, ChIP assay, gene expression analysis Genes & development High 17938240
2008 HIF-1α binds to specific hypoxia-response elements (HREs) in the JMJD1A gene promoter and directly induces JMJD1A expression under hypoxia. JMJD1A protein retains H3K9 demethylase activity under hypoxic conditions. ChIP assay identifying HIF-1α binding to JMJD1A promoter HRE; siRNA knockdown of HIF-1 abolishing hypoxia-induced JMJD1A upregulation; in vitro demethylase activity assay The Journal of biological chemistry High 18538129 18984585
2009 Nickel ions inhibit KDM3A demethylase activity by replacing the catalytic Fe(II) at the active site. Without iron, ~1 molecule of Ni(II) inhibits 1 molecule of KDM3A (IC50 ~2.5 µM). Nickel-bound KDM3A cannot be reactivated by excess iron. Nickel also inhibits KDM3A in intact cells. In vitro demethylase activity assay with varying Ni/Fe concentrations; X-ray absorption spectroscopy on ABH2 showing Ni binds same site as Fe; cell-based inhibition assays The Journal of biological chemistry High 20042601
2012 KDM3A is recruited to the SLC2A3 (GLUT3) locus in a HIF-1-dependent manner and demethylates H3K9me2 at this locus, facilitating chromatin looping and upregulating GLUT3 expression under hypoxia. Knockdown of both HIF-1α and KDM3A suppresses hypoxia-induced glycolytic gene expression. ChIP-seq, ChIP assay, 3C (chromatin conformation capture), RNAi knockdown, DNA microarray Molecular and cellular biology High 22645302
2013 Jmjd1a directly binds to the Sry gene locus and regulates H3K9me2 marks there, positively controlling Sry expression. Loss of Jmjd1a leads to male-to-female sex reversal in mice due to insufficient Sry expression. Jmjd1a knockout mouse model, ChIP assay at Sry locus, gene expression analysis Science High 24009392
2013 KDM3A forms a complex with KSHV LANA protein in the nucleus. This complex demethylates H3K9me2 at LANA recruitment sites on the KSHV episome, maintaining H3K9 hypomethylation at immediate-early and latent gene promoters and supporting viral gene expression and replication. H3K9 methylation inhibits LANA binding to the H3 tail. Co-immunoprecipitation from nuclear extracts, pulldown with purified proteins, ChIP with KSHV tiling arrays, KDM3A knockdown Journal of virology High 23576503
2013 KDM3A demethylates H3K9me2 at the promoter of HOXA1 and activates its transcription, promoting G1/S cell cycle progression. KDM3A siRNA reduces HOXA1 and CCND1 expression, resulting in G1 arrest in cancer cells. ChIP assay showing KDM3A binding and H3K9me2 demethylation at HOXA1 promoter; siRNA knockdown with cell cycle analysis International journal of cancer Medium 22020899
2013 JMJD1A binds to the MALAT1 gene promoter and demethylates histone H3K9, thereby upregulating MALAT1 expression, which in turn promotes neuroblastoma cell migration and invasion. N-Myc activates JMJD1A expression by binding the JMJD1A promoter. ChIP assay, RT-PCR, Affymetrix microarray, cell migration/invasion assays, JMJD1A inhibitor treatment Oncotarget Medium 24742640
2014 KDM3A is a positive regulator of estrogen receptor (ER) activity in breast cancer. KDM3A depletion abrogates ER recruitment to cis-regulatory elements at target gene promoters and inhibits estrogen-induced gene expression. Catalytic demethylase activity of KDM3A is required for ER-target gene expression and cell growth. RNAi knockdown, ChIP assay, global gene expression analysis, catalytic mutant rescue experiments Nucleic acids research High 25488809
2014 ACK1 tyrosine kinase phosphorylates KDM3A at tyrosine 1114 (Y1114) in a heregulin-dependent manner. This phosphorylation enhances KDM3A demethylase activity, decreasing H3K9me2 marks and increasing transcription of the ER co-regulated gene HOXA1 even in the presence of tamoxifen. In vitro kinase assay, phospho-site mapping, ChIP assay, ACK1 knockdown/inhibitor treatment, mutational analysis The Journal of biological chemistry High 25148682
2014 Kdm3a localizes to cytoplasmic structures in maturing spermatids (acrosome, manchette) in addition to its nuclear role. Kdm3a protein stability, subcellular distribution, and demethylase activity are dependent on Hsp90, identifying it as an Hsp90 client. Loss of Kdm3a demethylase activity causes abnormal acrosome, manchette, and absence of implantation fossa, affecting cytoskeletal components β-actin and γ-tubulin fractionation. Electron microscopy, cellular fractionation, Hsp90 inhibitor treatment, two Kdm3a mouse models (demethylase activity mutant), immunolocalization Molecular biology of the cell High 24554764
2015 JMJD1A is phosphorylated at serine 265 (S265) by protein kinase A (PKA) downstream of β-adrenergic signaling. This phosphorylation promotes JMJD1A interaction with the SWI/SNF nucleosome remodelling complex and DNA-bound PPARγ, facilitating long-range chromatin interactions and rapid target gene activation (Adrb1, Ucp1) in brown adipocytes. The S265 phosphorylation-dependent chromatin scaffold function is independent of demethylase activity, while H3K9me2 demethylation is a separate function required for sustained gene activation. PKA phosphorylation assay, Co-IP of JMJD1A with SWI/SNF and PPARγ, ChIP, chromatin conformation capture, S265A mutant rescue experiments Nature communications High 25948511
2015 JMJD1A promotes c-Myc transcriptional activation by enhancing androgen receptor (AR) recruitment to the c-Myc gene enhancer and inducing H3K9 demethylation, increasing AR-dependent c-Myc mRNA. In parallel, JMJD1A (including catalytically inactive mutant) binds HUWE1 E3 ubiquitin ligase, attenuating HUWE1-dependent ubiquitination and degradation of c-Myc protein. ChIP assay, Co-IP (JMJD1A-HUWE1), ubiquitination assay, catalytic mutant analysis, knockdown/rescue experiments Oncogene High 26279298
2015 JMJD1A demethylates H3K9me2 at the PPARγ gene promoter in hepatic stellate cells, maintaining PPARγ expression and restraining fibrosis. JMJD1A knockdown reinforces H3K9me2 at the PPARγ promoter and increases fibrosis markers; overexpression of wild-type but not catalytically inactive JMJD1A rescues the phenotype. ChIP assay, siRNA/shRNA knockdown, wild-type vs. catalytic mutant overexpression, in vivo mouse liver fibrosis model FASEB journal High 25609425
2016 KDM3A maintains expression of KLF2 and IRF4 in multiple myeloma cells through H3K9 demethylation at their loci. KDM3A, KLF2, and IRF4 form a survival axis where KLF2 directly activates IRF4 and IRF4 reciprocally upregulates KLF2. KDM3A/KLF2/IRF4 knockdown also decreases ITGB7 expression, reducing MM cell adhesion to bone marrow stromal cells and homing. ChIP assay showing H3K9 demethylation at KLF2/IRF4 loci, siRNA knockdown (in vitro and in vivo xenograft), luciferase reporter assay for KLF2→IRF4 axis Nature communications High 26728187
2016 KDM3A demethylates non-histone substrate p53 at monomethylated K372 (p53-K372me1), suppressing p53's pro-apoptotic function. KDM3A also demethylates H3K9 to promote pro-invasive gene transcription. Depletion of KDM3A can reactivate mutant p53 to induce pro-apoptotic gene expression. Co-IP, in vitro demethylation assay on p53-K372me1 peptide, ChIP, RNAi knockdown, gene expression analysis Oncogene High 27270439
2016 Normal ECM mechanosensing triggers downregulation and nuclear exit of JMJD1A in carcinoma cells, resulting in epigenetic growth restriction. JMJD1A positively regulates transcription of multiple target genes including YAP/TAZ in a matrix-stiffness-dependent manner. JMJD1A knockdown and localization studies, cell growth assays on different ECM stiffness, gene expression profiling Nature communications Medium 27488962
2016 KDM3A directly demethylates H3K9me2 at the MCAM promoter and also regulates MCAM expression indirectly via the Ets1 transcription factor, promoting Ewing Sarcoma cell migration and metastasis. ChIP assay at MCAM promoter, RNAi knockdown, in vitro migration assay, in vivo experimental metastasis model Oncogene High 28319067
2013 Control of H3K9 methylation state by JMJD1A homodimerization: JMJD1A forms a homodimer through its catalytic domains, placing two active sites in proximity. This enables substrate channeling—efficient conversion of H3K9me2 to unmethylated H3K9 by reducing release of the monomethylated intermediate. Inactivating one active site in the dimer significantly reduces demethylation rate without changing affinity for the intermediate. In vitro demethylation assay, size-exclusion chromatography/native gel demonstrating homodimerization, heterodimer (WT + inactive mutant) enzymatic analysis The Journal of biological chemistry High 24214985
2017 JMJD1A (KDM3A) promotes alternative splicing of AR-V7 through heterogeneous nuclear ribonucleoprotein F (HNRNPF). JMJD1A interacts with HNRNPF and promotes its recruitment to a cryptic exon 3b on AR pre-mRNA. Knockdown of JMJD1A or HNRNPF inhibits AR-V7 splicing but not full-length AR in a minigene reporter assay. Co-IP (JMJD1A-HNRNPF), RIP (RNA immunoprecipitation), minigene reporter assay, siRNA knockdown Proceedings of the National Academy of Sciences High 29712835
2017 KDM3A is recruited to the promoter of glycolytic gene PGK1, demethylates H3K9me2, and cooperates with HIF1α to induce glycolytic gene expression. A catalytically inactive JMJD1A mutant (H1120Y) fails to demethylate H3K9me2 at the PGK1 promoter and fails to cooperate with HIF1α, establishing that demethylase activity is required for HIF1α coactivation. ChIP assay at PGK1 promoter, catalytic mutant (H1120Y) analysis, siRNA knockdown, cell proliferation/colony formation assays Oncogene High 28263974
2017 KDM3A promotes tumorigenesis in the PI3K-activated liver by recruiting c-Jun to AP-1 binding sites of target genes (Cd44, Mmp7, Pdgfrb) and facilitating Brg1 (SWI/SNF component) binding, in a Kdm3a-dependent manner, without affecting c-Jun expression. Loss of Kdm3a attenuates tumor formation in Pik3ca transgenic mice. ChIP assay showing KDM3A, c-Jun, and Brg1 binding at AP-1 sites, Kdm3a knockout in Pik3ca transgenic mice, transcriptome analysis Oncogene High 28692045
2017 KDM3A coordinates cilia stability by regulating actin gene expression (nuclear function) and by directly binding to the actin cytoskeleton (non-nuclear function), creating an 'actin gate' involving ARP2/3 activity that controls IFT protein recruitment into cilia. Loss of KDM3A causes abnormally wide range of cilia lengths, delayed disassembly, and accumulation of IFT proteins. Promoting actin filament formation rescues KDM3A mutant ciliary defects. KDM3A knockout mouse model (phenocopying ciliopathy), actin cytoskeleton binding assay, IFT protein accumulation imaging, ARP2/3 inhibitor rescue, actin depolymerization mimicry experiments The Journal of cell biology High 28246120
2018 KDM3A is tyrosine-phosphorylated by JAK2 in the nucleus and functions as a STAT3-dependent transcriptional coactivator. JAK2-mediated KDM3A phosphorylation induced by IL-6 alters histone H3K9 methylation as the predominant epigenetic event in JAK2-STAT3 pathway activation. In vitro kinase assay (JAK2 phosphorylating KDM3A), Co-IP, ChIP showing H3K9 methylation changes, cell-based IL-6 stimulation experiments Proceedings of the National Academy of Sciences High 30377265
2018 JMJD1A coordinates acute and chronic cold adaptation through two mechanisms requiring S265 phosphorylation by PKA: (1) phosphorylation-dependent but demethylation-independent acute Ucp1 induction in BAT via long-range chromatin interactions; (2) phosphorylation plus H3K9me2 demethylation for chronic Ucp1 expression in beige subcutaneous WAT via a PRDM16-PPARγ-P-JMJD1A complex. S265A phospho-mutant mouse model, ChIP, chromatin conformation capture, Co-IP of JMJD1A-PRDM16-PPARγ complex, cold exposure experiments Nature communications High 29674659
2019 KDM3A binds PGC-1α and demethylates monomethylated K224 of PGC-1α (a non-histone substrate) under normoxic conditions. Hypoxia inhibits KDM3A (which has high KM for oxygen), causing accumulation of PGC-1α K224 monomethylation that decreases PGC-1α activity for NRF1/NRF2-dependent transcription of TFAM, TFB1M, TFB2M, reducing mitochondrial biogenesis. PGC-1α K224R mutant significantly increases mitochondrial biogenesis and tumor cell apoptosis. Co-IP (KDM3A-PGC-1α), in vitro demethylation assay on PGC-1α K224me1, oxygen-dependent activity assay, PGC-1α K224R mutant in cells and brain tumor xenograft model Molecular cell High 31629659
2019 PHF5A acetylation at K29 (by p300 in response to nutrient stress) strengthens U2 snRNP interactions and induces alternative splicing that stabilizes KDM3A mRNA, increasing KDM3A protein expression. This PHF5A acetylation → KDM3A upregulation axis promotes colorectal cancer stress resistance. Proteomics identifying PHF5A hyperacetylation, Co-IP (PHF5A-U2 snRNP components), splicing reporter assay, RNA-seq, KDM3A rescue experiments Molecular cell High 31054974
2019 KDM3A binds to the DCLK1 promoter and activates DCLK1 expression. KDM3A knockdown reduces DCLK1 levels in pancreatic cancer cells; overexpression of KDM3A in normal pancreatic ductal cells enables tumor and metastasis formation in vivo. ChIP identifying KDM3A binding sites at DCLK1 promoter, siRNA knockdown, KDM3A overexpression in HPNE cells, orthotopic xenograft model Gastroenterology High 31442435
2019 KDM3A demethylates H3K9me2 at enhancers of hippo pathway target genes and promotes H3K27ac deposition there. KDM3A associates with p300 and is required for p300 recruitment to enhancers. KDM3A depletion causes H3K9me2 accumulation mainly at TEAD1-binding enhancers, reducing TEAD1 binding and impairing transcription. KDM3A also upregulates YAP1 expression. ChIP-seq (H3K9me2, H3K27ac, H3K4me3), Co-IP (KDM3A-p300), siRNA knockdown, YAP1 rescue experiments Nucleic acids research High 30649550
2019 KDM3A and KDM4C regulate heterochromatin reorganization during MSC senescence by transcriptionally activating condensin components NCAPD2 and NCAPG2 through H3K9 demethylation. Kdm3a-/- mouse MSCs exhibit defective chromosome organization and exacerbated DNA damage response, associated with accelerated bone aging. KDM3A/KDM4C knockdown and Kdm3a-/- mouse model, ChIP assay at condensin gene promoters, DNA damage response assays iScience Medium 31704649
2020 JMJD1A protein stability is regulated by the E3 ubiquitin ligase STUB1, which mediates JMJD1A degradation. The acetyltransferase p300 acetylates JMJD1A at lysine 421 (K421), recruiting BRD4 to block STUB1-mediated degradation and promoting JMJD1A recruitment to AR target sites. Additionally, HUWE1 induces K27-/K29-linked noncanonical ubiquitination of JMJD1A at lysine-918. Co-IP (JMJD1A-STUB1, JMJD1A-p300, JMJD1A-BRD4), ubiquitination assay, acetylation mapping (K421), ChIP, CRPC clinical specimen correlation Cancer research High 32238799 32522824
2020 KDM3A regulates alternative splicing of cell-cycle genes following DNA damage. KDM3A undergoes PKA-mediated phosphorylation at S265 upon DNA damage, which is required for proper cell-cycle regulation. KDM3A regulates SAT1 alternative splicing through a demethylase-independent mechanism requiring its interaction with ARID1A (SWI/SNF subunit) and SRSF3 splicing factor; KDM3A is essential for SRSF3 binding to SAT1 pre-mRNA. RNA-seq, Co-IP (KDM3A-ARID1A, KDM3A-SRSF3), phosphorylation assay at S265, catalytic mutant analysis, RIP (SRSF3 on SAT1 pre-mRNA) RNA High 34321328
2021 KDM3A and KDM3B form a complex (demonstrated by IP-MS) that performs H3K9 demethylation cooperatively. OCT4 and SOX2 co-operate with the KDM3A/KDM3B-containing complex to maintain H3K9 hypomethylation at pluripotency gene loci and sustain the pluripotency gene regulatory network in porcine iPSCs. IP-mass spectrometry (KDM3A-KDM3B complex), ChIP-seq (H3K9me2/me3), co-depletion of KDM3A and KDM3B, gene expression analysis FASEB journal Medium 34042215
2021 MDFI and MDFIC proteins interact with JMJD1A. JMJD1A influences transcription of several genes co-regulated by MDFI or MDFIC, including the HIC1 tumor suppressor gene which is co-stimulated by JMJD1A and MDFIC. Catalytically inactive JMJD1A mutant does not cooperate with ETV1 to induce MMP1, establishing demethylase requirement for this co-activation. Co-IP (JMJD1A-MDFI/MDFIC), RNA-seq, luciferase reporter with JMJD1A catalytic mutant, gene expression analysis Scientific reports Medium 32457453
2016 KDM3A promotes anoikis in epithelial cells following matrix detachment by transcriptionally activating BNIP3 and BNIP3L via H3K9 demethylation. Integrin signaling in attached cells maintains low KDM3A expression; upon detachment, reduced integrin signaling increases KDM3A expression. KDM3A knockdown substantially reduces apoptosis following detachment; KDM3A ectopic expression induces cell death in attached cells. RNAi screen identifying KDM3A, ChIP assay at BNIP3/BNIP3L promoters, ectopic KDM3A expression, mouse breast cancer metastasis model eLife High 27472901
2016 In hypoxic myeloma cells, the HIF-1α→KDM3A→MALAT1 axis promotes antiapoptotic phenotype independent of IRF4. KDM3A expression is HIF-1α-dependent, and KDM3A knockdown induces myeloma cell apoptosis under chronic hypoxia, while knockdown increases H3K9 methylation at MALAT1 locus. siRNA knockdown, ChIP at MALAT1 locus, gene expression analysis, apoptosis assays under chronic hypoxia Blood advances Medium 29444873
2017 JMJD1A promotes Snail transcriptional activation by directly binding to the Snail gene promoter and demethylating H3K9me1 and H3K9me2 at its specific promoter region, thereby promoting prostate cancer progression. ChIP assay at Snail promoter, Co-IP (JMJD1A-Snail gene complex), siRNA knockdown, ectopic expression, xenograft model Molecular cancer research Medium 32019811
2018 JMJD1A promotes β-catenin expression, interacts with β-catenin to enhance its transactivation, and demethylates H3K9me2 at c-Myc and MMP9 gene promoters to activate Wnt/β-catenin target genes. A catalytic mutant (H1120Y) fails to demethylate H3K9me2 at these promoters and fails to promote CRC progression, establishing demethylase activity requirement. ChIP assay at c-Myc and MMP9 promoters, Co-IP (JMJD1A-β-catenin), H1120Y catalytic mutant analysis, xenograft tumor model The Journal of biological chemistry High 29802196
2023 JMJD1A is a major iron-dependent epigenetic enzyme for adipocyte differentiation, demethylating H3K9me2 at Pparg and other adipogenesis gene loci. Iron supply through lysosome-mediated ferritinophagy is crucial for JMJD1A activity during early adipocyte differentiation; iron deficiency suppresses H3K9me2 demethylation and blocks terminal differentiation. JMJD1A knockdown, ChIP-seq (H3K9me2), iron chelation/ferritinophagy inhibition, mass spectrometry of histone marks, integrated genome-wide analysis Nucleic acids research High 37158274
2024 JMJD1A mediates β-adrenergic-induced H3K9 demethylation at Pgc1a/b enhancers in subcutaneous white adipose tissue (scWAT), promoting PGC-1α/β-dependent mitochondrial biogenesis and beige adipocyte formation. Disruption of JMJD1A demethylase activity in mice impairs Pgc1a/b activation in scWAT and causes obesity, insulin resistance, and metabolic disorders, whereas JMJD1A demethylase activity is dispensable for BAT thermogenesis during acute cold stress. JMJD1A demethylase-activity mutant knock-in mice, ChIP at Pgc1a/b enhancers, β-adrenergic stimulation, metabolic phenotyping iScience High 38544573
2006 TSGA/Jmjd1a (KDM3A) is a nuclear protein that contains functional transcription repression domains and interacts with the ETS transcription factor ER71 both in vitro and in vivo via its N-terminus (TSGA) and ER71's C-terminus. TSGA impairs ER71-mediated transcriptional activation from the MMP-1 promoter. GST pulldown, co-immunoprecipitation, reporter gene assay, immunostaining Journal of cellular biochemistry Medium 16619273
2017 KDM3A regulates H3K9me2 at the proximal promoter regions of AGTR1 and ROCK2 to control their transcription, mediating the Rho/ROCK and AngII/AGTR1 signaling pathways in vascular smooth muscle cells. KDM3A overexpression accelerates while knockdown reduces neointima formation after carotid artery balloon injury in diabetic rats. ChIP assay at AGTR1 and ROCK2 promoters, adenoviral KDM3A overexpression and lentiviral siRNA knockdown in vivo and in vitro, rat carotid artery injury model Atherosclerosis Medium 28135625
2019 KDM3A activates the JMJD1A-mediated demethylation of H3K9me2 at Erk2 and Klf2 promoters in bone marrow MSCs, elevating their expression and promoting osteogenic differentiation. ChIP assay at Erk2 and Klf2 promoters, miR-199a-3p targeting of KDM3A (dual-luciferase), overexpression and knockdown in MSCs The Biochemical journal Medium 33410908
2018 JMJD1A and JMJD1B preferentially target H3K9 demethylation in gene-dense euchromatic regions of chromosomes, establishing global H3K9 hypomethylation in euchromatin. G9a-mediated H3K9 overmethylation is the direct cause of cell death and perturbed gene expression in JMJD1A/JMJD1B-depleted ESCs, established by epistasis using G9a heterozygous mutation or chemical inhibitor rescue. Double knockout ESCs and embryos, ChIP-seq (H3K9me1/me2), G9a heterozygous rescue, G9a inhibitor rescue Stem cell reports High 29526734
2017 The GLP/G9a H3K9 methyltransferase complex catalyzes H3K9 methylation at the Sry locus. Heterozygous GLP mutation or chemical GLP/G9a inhibitor rescues sex-reversal in Jmjd1a-deficient mice by restoring Sry expression, demonstrating that Jmjd1a/KDM3A and GLP/G9a form a methylation-demethylation balance at the Sry locus. Genetic epistasis (Jmjd1a KO × Glp heterozygous mice), GLP/G9a chemical inhibitor treatment in Jmjd1a-deficient embryos, ChIP assay at Sry locus PLoS genetics High 28949961
2017 Vitamin C specifically induces rapid, reversible demethylation of H3K9me2 (but not other histone methylation marks) in naïve embryonic stem cells via Kdm3a and Kdm3b. Kdm3a and Kdm3b are required for vitamin C-induced H3K9me2 demethylation at chromosomal domains, gene promoters, and repeat elements. This H3K9me2 demethylation is independent of Tet-mediated DNA demethylation at specific loci. Western blot, immunofluorescence, mass spectrometry of histone marks, ChIP-seq, Kdm3a/Kdm3b knockdown, epistasis with Tet enzyme inhibition Epigenetics & chromatin High 28706564
2022 KDM3A binds to the ETS1 promoter and removes H3K9me2 to promote ETS1 transcription, protecting against myocardial I/R injury. KDM3A knockout exacerbates cardiac dysfunction, mitochondrial apoptosis, ROS, and inflammation both in vivo and in vitro. ChIP-PCR at ETS1 promoter, KDM3A knockout/overexpression (in vitro and rat in vivo I/R model), H3K9me2 demethylation assay Communications biology Medium 35338235
2021 KDM3A activates DCLK1 expression by demethylating H3K9me2 at its promoter; DCLK1 in turn suppresses FXYD3 expression. Let-7i targets and downregulates KDM3A mRNA, reversing this axis in lung cancer cells. ChIP assay at DCLK1 promoter, dual-luciferase reporter (let-7i targeting KDM3A 3'UTR), siRNA knockdown, xenograft model Journal of cellular and molecular medicine Medium 33350586
2023 NUPR1 promotes TFEB transcription in hypoxic glioma cells by binding to KDM3A, which reduces H3K9me2 levels at the TFEB promoter, thereby augmenting autophagy and TMZ resistance. Co-IP (NUPR1-KDM3A interaction), ChIP at TFEB promoter (KDM3A binding and H3K9me2 levels), siRNA knockdown, xenograft model Oncology research Medium 37305393

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. Genes & development 416 17938240
2008 The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. The Journal of biological chemistry 284 18984585
2012 Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. Molecular and cellular biology 204 22645302
2013 Epigenetic regulation of mouse sex determination by the histone demethylase Jmjd1a. Science (New York, N.Y.) 201 24009392
2021 HIF-1α/JMJD1A signaling regulates inflammation and oxidative stress following hyperglycemia and hypoxia-induced vascular cell injury. Cellular & molecular biology letters 159 34479471
2008 Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochemical and biophysical research communications 158 18538129
2019 KDM3A Senses Oxygen Availability to Regulate PGC-1α-Mediated Mitochondrial Biogenesis. Molecular cell 143 31629659
2014 The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1. Oncotarget 106 24742640
2016 Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription. Nature communications 105 27488962
2015 JMJD1A is a signal-sensing scaffold that regulates acute chromatin dynamics via SWI/SNF association for thermogenesis. Nature communications 102 25948511
2009 Nickel ions inhibit histone demethylase JMJD1A and DNA repair enzyme ABH2 by replacing the ferrous iron in the catalytic centers. The Journal of biological chemistry 101 20042601
2018 Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 98 29712835
2016 HIF-KDM3A-MMP12 regulatory circuit ensures trophoblast plasticity and placental adaptations to hypoxia. Proceedings of the National Academy of Sciences of the United States of America 97 27807143
2017 Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1α. Oncogene 95 28263974
2015 Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival. Oncogene 93 26279298
2016 The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nature communications 92 26728187
2014 The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. Nucleic acids research 91 25488809
2016 Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53. Oncogene 85 27270439
2019 Acetylation of PHF5A Modulates Stress Responses and Colorectal Carcinogenesis through Alternative Splicing-Mediated Upregulation of KDM3A. Molecular cell 83 31054974
2011 The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. International journal of cancer 79 22020899
2019 LncRNA H19 ameliorates myocardial infarction-induced myocardial injury and maladaptive cardiac remodelling by regulating KDM3A. Journal of cellular and molecular medicine 78 31755219
2013 Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor-associated macrophages. Cancer research 78 23492365
2017 The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells. Oncotarget 72 28416760
2018 Histone demethylase JMJD1A coordinates acute and chronic adaptation to cold stress via thermogenic phospho-switch. Nature communications 71 29674659
2011 Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: clinical impact on recurrence after hepatic resection. Annals of surgical oncology 71 21607773
2010 Hypoxia and nickel inhibit histone demethylase JMJD1A and repress Spry2 expression in human bronchial epithelial BEAS-2B cells. Carcinogenesis 68 20881000
2013 The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma. Oncogene 66 24362521
2006 Repression of transcription by TSGA/Jmjd1a, a novel interaction partner of the ETS protein ER71. Journal of cellular biochemistry 65 16619273
2019 The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice. Gastroenterology 64 31442435
2017 The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis. Oncogene 62 28319067
2018 Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/β-catenin signaling. The Journal of biological chemistry 59 29802196
2020 p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer. Cancer research 58 32522824
2018 Hypoxia-inducible KDM3A addiction in multiple myeloma. Blood advances 58 29444873
2014 ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. The Journal of biological chemistry 58 25148682
2020 Advances in Histone Demethylase KDM3A as a Cancer Therapeutic Target. Cancers 56 32354028
2017 Vitamin C induces specific demethylation of H3K9me2 in mouse embryonic stem cells via Kdm3a/b. Epigenetics & chromatin 56 28706564
2013 Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen regulates the KSHV epigenome by association with the histone demethylase KDM3A. Journal of virology 55 23576503
2019 Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer. Nucleic acids research 52 30649550
2016 Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. Oncogene 50 27694900
2020 Crucial Functions of the JMJD1/KDM3 Epigenetic Regulators in Cancer. Molecular cancer research : MCR 49 32605929
2014 The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth. Molecular and cellular biology 47 25071150
2020 Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis. Journal of cellular and molecular medicine 46 33350586
2019 KDM3A and KDM4C Regulate Mesenchymal Stromal Cell Senescence and Bone Aging via Condensin-mediated Heterochromatin Reorganization. iScience 46 31704649
2020 Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells. Cell death & disease 45 32238799
2015 Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and liver fibrosis by epigenetically regulating peroxisome proliferator-activated receptor γ. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 45 25609425
2013 The histone demethylase JMJD1A regulates adrenomedullin-mediated cell proliferation in hepatocellular carcinoma under hypoxia. Biochemical and biophysical research communications 45 23583388
2011 The expression of histone demethylase JMJD1A in renal cell carcinoma. Neoplasma 45 21275466
2017 Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. Oncogene 44 28692045
2020 Upregulation of miR-101a Suppresses Chronic Renal Fibrosis by Regulating KDM3A via Blockade of the YAP-TGF-β-Smad Signaling Pathway. Molecular therapy. Nucleic acids 42 32092824
2020 JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma. Cell death & disease 42 33318475
2016 Histone demethylase KDM3a, a novel regulator of vascular smooth muscle cells, controls vascular neointimal hyperplasia in diabetic rats. Atherosclerosis 41 28135625
2017 KDM3A coordinates actin dynamics with intraflagellar transport to regulate cilia stability. The Journal of cell biology 40 28246120
2018 KDM3A histone demethylase functions as an essential factor for activation of JAK2-STAT3 signaling pathway. Proceedings of the National Academy of Sciences of the United States of America 37 30377265
2023 Crucial role of iron in epigenetic rewriting during adipocyte differentiation mediated by JMJD1A and TET2 activity. Nucleic acids research 35 37158274
2019 KDM3A inhibition modulates macrophage polarization to aggravate post-MI injuries and accelerates adverse ventricular remodeling via an IRF4 signaling pathway. Cellular signalling 35 31513837
2009 Identification and characterization of demethylase JMJD1A as a gene upregulated in the human cellular response to hypoxia. Cell and tissue research 32 19471969
2017 KDM3A inhibition attenuates high concentration insulin‑induced vascular smooth muscle cell injury by suppressing MAPK/NF‑κB pathways. International journal of molecular medicine 30 29286083
2014 Kdm3a lysine demethylase is an Hsp90 client required for cytoskeletal rearrangements during spermatogenesis. Molecular biology of the cell 30 24554764
2018 Combined Loss of JMJD1A and JMJD1B Reveals Critical Roles for H3K9 Demethylation in the Maintenance of Embryonic Stem Cells and Early Embryogenesis. Stem cell reports 29 29526734
2020 Dihydroartemisinin suppresses bladder cancer cell invasion and migration by regulating KDM3A and p21. Journal of Cancer 28 31956358
2020 The long non-coding RNA SNHG4/microRNA-let-7e/KDM3A/p21 pathway is involved in the development of non-small cell lung cancer. Molecular therapy oncolytics 28 33816782
2016 The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L. eLife 28 27472901
2012 The histone demethylase Kdm3a is essential to progression through differentiation. Nucleic acids research 27 22581778
2018 KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion. International journal of biological macromolecules 26 30578902
2013 Control of histone H3 lysine 9 (H3K9) methylation state via cooperative two-step demethylation by Jumonji domain containing 1A (JMJD1A) homodimer. The Journal of biological chemistry 26 24214985
2021 Histone demethylase complexes KDM3A and KDM3B cooperate with OCT4/SOX2 to define a pluripotency gene regulatory network. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 25 34042215
2017 Rescuing the aberrant sex development of H3K9 demethylase Jmjd1a-deficient mice by modulating H3K9 methylation balance. PLoS genetics 25 28949961
2021 KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer. Experimental biology and medicine (Maywood, N.J.) 24 34171978
2021 Tumor-Suppressive Role of microRNA-202-3p in Hepatocellular Carcinoma Through the KDM3A/HOXA1/MEIS3 Pathway. Frontiers in cell and developmental biology 23 33520978
2020 Opposite Roles of the JMJD1A Interaction Partners MDFI and MDFIC in Colorectal Cancer. Scientific reports 23 32457453
2020 H3K9 Demethylases JMJD1A and JMJD1B Control Prospermatogonia to Spermatogonia Transition in Mouse Germline. Stem cell reports 23 32679061
2017 KDM3A promotes inhibitory cytokines secretion by participating in TLR4 regulation of Foxp3 transcription in lung adenocarcinoma cells. Oncology letters 23 28521455
2020 MiR-216a-5p alleviates chronic constriction injury-induced neuropathic pain in rats by targeting KDM3A and inactivating Wnt/β-catenin signaling pathway. Neuroscience research 22 32889066
2024 Mitochondrial biogenesis in white adipose tissue mediated by JMJD1A-PGC-1 axis limits age-related metabolic disease. iScience 21 38544573
2022 LncRNA HOX transcript antisense RNA mitigates cardiac function injury in chronic heart failure via regulating microRNA-30a-5p to target KDM3A. Journal of cellular and molecular medicine 21 35083842
2022 microRNA-27a-3p delivered by extracellular vesicles from glioblastoma cells induces M2 macrophage polarization via the EZH1/KDM3A/CTGF axis. Cell death discovery 21 35568721
2016 JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 21 26945572
2022 KDM3A Attenuates Myocardial Ischemic and Reperfusion Injury by Ameliorating Cardiac Microvascular Endothelial Cell Pyroptosis. Oxidative medicine and cellular longevity 20 36092165
2021 Down-regulated microRNA-199a-3p enhances osteogenic differentiation of bone marrow mesenchymal stem cells by targeting Kdm3a in ovariectomized rats. The Biochemical journal 20 33410908
2021 KDM3A regulates alternative splicing of cell-cycle genes following DNA damage. RNA (New York, N.Y.) 20 34321328
2020 Cooperation between ETS transcription factor ETV1 and histone demethylase JMJD1A in colorectal cancer. International journal of oncology 20 33174020
2019 The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer. Cancers 20 31390833
2017 JMJD-1.2/PHF8 controls axon guidance by regulating Hedgehog-like signaling. Development (Cambridge, England) 20 28126843
2017 The histone demethylase Kdm3a is required for normal epithelial proliferation, ductal elongation and tumor growth in the mouse mammary gland. Oncotarget 20 29156681
2022 The histone demthylase KDM3A protects the myocardium from ischemia/reperfusion injury via promotion of ETS1 expression. Communications biology 19 35338235
2020 Lysine demethylase KDM3A regulates nanophotonic hyperthermia resistance generated by 2D silicene in breast cancer. Biomaterials 19 32569864
2020 KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma. Genes & cancer 17 32577157
2006 Identification of Jmjd1a as a STAT3 downstream gene in mES cells. Cell structure and function 17 16988490
2022 KDM3A-mediated SP1 activates PFKFB4 transcription to promote aerobic glycolysis in osteosarcoma and augment tumor development. BMC cancer 16 35590288
2020 Histone Demethylase KDM3A Promotes Cervical Cancer Malignancy Through the ETS1/KIF14/Hedgehog Axis. OncoTargets and therapy 16 33239895
2012 Ascorbate antagonizes nickel ion to regulate JMJD1A expression in kidney cancer cells. Acta biochimica et biophysica Sinica 16 22318714
2023 Inflammatory stimulation of astrocytes affects the expression of miRNA-22-3p within NSCs-EVs regulating remyelination by targeting KDM3A. Stem cell research & therapy 15 36959678
2021 MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1α axis. Journal of translational medicine 15 34044859
2016 Expression ratio of histone demethylase KDM3A to protamine-1 mRNA is predictive of successful testicular sperm extraction in men with obstructive and non-obstructive azoospermia. Andrology 15 27027467
2016 Deficient expression of JMJD1A histone demethylase in patients with round spermatid maturation arrest. Reproductive biomedicine online 15 27692601
2021 microRNA-155-3p attenuates intervertebral disc degeneration via inhibition of KDM3A and HIF1α. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 13 33486545
2021 Downregulation of miR-335 exhibited an oncogenic effect via promoting KDM3A/YAP1 networks in clear cell renal cell carcinoma. Cancer gene therapy 13 33888871
2020 Histone Demethylase JMJD1A Promotes Tumor Progression via Activating Snail in Prostate Cancer. Molecular cancer research : MCR 13 32019811
2023 Mechanism of NURP1 in temozolomide resistance in hypoxia-treated glioma cells via the KDM3A/TFEB axis. Oncology research 12 37305393
2022 The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A. American journal of physiology. Renal physiology 12 36074918

Missed literature

Know a paper Affinage missed for KDM3A? Flag it for the maintainers and the community.

No submissions yet.